-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on ResMed, Raises Price Target to $300

Benzinga·08/01/2025 16:14:12
Listen to the news
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $294 to $300.